Lv63
2500 积分 2022-07-05 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5小时前
已完结
Updates of placental macrophages: Origins, molecular markers, functions, and related diseases
13天前
已完结
Industry shows increased appetite for macrophage biology
1个月前
已完结
单抗类生物制品非临床安全性研究和评价的考虑要点
1个月前
已完结
抗体类药物非临床研究相关种属选择的一般考虑
1个月前
已完结
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment
2个月前
已完结
基于美国FDA近五年批准的新药浅谈ICH S1指导原则的实施
4个月前
已完结
生物制品的致癌性评估及风险管理策略
4个月前
已完结
浅谈抗体偶联药物非临床安全性评价
4个月前
已完结
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
7个月前
已完结
皖公网安备34019202002308
